Stem cell factor receptor/c-Kit: From basic Science to clinical implications

Physiological Reviews

Volumn 92, Issue 4, 2012, Pages 1619-1649

  Lennartsson, Johan ^a,b,c   Rönnstrand, Lars ^a,b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Department of Laboratory Medicine ^*  (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ADAPTOR PROTEIN; CRK LIKE PROTEIN; DASATINIB; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; INTERLEUKIN 33; INTERLEUKIN 7; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C BETA; PHOSPHOLIPASE C DELTA; PHOSPHOLIPASE C GAMMA; PHOSPHOLIPASE D; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN SH2; PROTEIN SH3; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 10; CHROMOSOME 12; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONSTIPATION; DOWNSTREAM PROCESSING; EMBRYO DEVELOPMENT; ENDOTHELIAL PROGENITOR CELL; FEEDBACK SYSTEM; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL STROMAL TUMOR; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; GENE TARGETING; GENETIC ASSOCIATION; GERM CELL; GERM CELL TUMOR; HEART FAILURE; HEART INFARCTION; HEMATOPOIETIC STEM CELL; HIPPOCAMPUS; HUMAN; IC 50; INTERSTITIAL CELL OF CAJAL; LIGAND BINDING; LINKAGE ANALYSIS; LOSS OF FUNCTION MUTATION; LUNG COMPLIANCE; LUNG SMALL CELL CANCER; MAST CELL; MAST CELL LEUKEMIA; MELANOCYTE; MELANOMA; MOLECULAR MODEL; NERVE CELL CULTURE; NONHUMAN; ONCOGENE; OOCYTE DEVELOPMENT; OVARY FOLLICLE DEVELOPMENT; PHENOTYPE; PIEBALDISM; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; REPERFUSION INJURY; SARCOMA VIRUS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SKIN PIGMENTATION; SMOOTH MUSCLE FIBER; SPERMATOGENESIS; STEM CELL EXPANSION; STEM CELL MOBILIZATION; SYSTEMIC MASTOCYTOSIS; TESTIS CARCINOMA; URTICARIA PIGMENTOSA; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ANIMALS; CELL SURVIVAL; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 84867718489     PISSN: 00319333     EISSN: 15221210     Source Type: Journal    
DOI: 10.1152/physrev.00046.2011     Document Type: Article

References (317)

1. Agosti V, Corbacioglu S, Ehlers I, Waskow C, Sommer G, Berrozpe G, Kissel H, Tucker CM, Manova K, Moore MA, Rodewald HR, Besmer P. Critical role for Kitmediated Src kinase but not PI 3-kinase signaling in Pro T and Pro B cell development. J Exp Med 199: 867-878, 2004.
2. Agosti V, Karur V, Sathyanarayana P, Besmer P, Wojchowski DM. A KIT juxtamembrane PY567-directed pathway provides nonredundant signals for erythroid progenitor cell development and stress erythropoiesis. Exp Hematol 37: 159-171, 2009.
3. Alai M, Mui AL, Cutler RL, Bustelo XR, Barbacid M, Krystal G. Steel factor stimulates the tyrosine phosphorylation of the proto-oncogene product, p95vav, in human hemopoietic cells. J Biol Chem 267: 18021-18025, 1992.
4. Albanesi C, Geremia R, Giorgio M, Dolci S, Sette C, Rossi P. A cell- and developmental stage-specific promoter drives the expression of a truncated c-kit protein during mouse spermatid elongation. Development 122: 1291-1302, 1996.
5. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269, 1997.
6. Anderson DM, Williams DE, Tushinski R, Gimpel S, Eisenman J, Cannizzaro LA, Aronson M, Croce CM, Huebner K, Cosman D. Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. Cell Growth Differ 2: 373-378, 1991.
7. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190, 2005.
8. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121: 257-264, 2007.
9. Arakawa T, Yphantis DA, Lary JW, Narhi LO, Lu HS, Prestrelski SJ, Clogston CL, Zsebo KM, Mendiaz EA, Wypych J. Glycosylated and unglycosylated recombinantderived human stem cell factors are dimeric and have extensive regular secondary structure. J Biol Chem 266: 18942-18948, 1991.
10. Arcaro A, Aubert M, Espinosa del Hierro ME, Khanzada UK, Angelidou S, Tetley TD, Bittermann AG, Frame MC, Seckl MJ. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signaling. Cell Signal 19: 1081-1092, 2007.
11. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 3: 497-516, 2010.
12. Baba H, Uchiwa H, Watanabe S. UVB irradiation increases the release of SCF from human epidermal cells. J Invest Dermatol 124: 1075-1077, 2005.
13. Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Köhler G, Duyster J, Berdel WE, Müller-Tidow C, Serve H, Sargin B. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 114: 4197-4208, 2009.
14. Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280: 37489-37494, 2005.
15. Bauer GL, Praetorius C, Bergsteinsdóttir K, Hallsson JH, Gísladottír BK, Schepsky A, Swing DA, O'Sullivan TN, Arnheiter H, Bismuth K, Debbache J, Fletcher C, Warming S, Copeland NG, Jenkins NA, Steingrímsson E. The role of MITF phosphorylation sites during coat color and eye development in mice analyzed by bacterial artificial chromosome transgene rescue. Genetics 183: 581-594, 2009.
16. Bayle J, Lopez S, Iwai K, Dubreuil P, De Sepulveda P. The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Lett 580: 2609-2614, 2006.
17. Bedell MA, Copeland NG, Jenkins NA. Multiple pathways for Steel regulation suggested by genomic and sequence analysis of the murine Steel gene. Genetics 142: 927-934, 1996.
18. Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F, Nadali G, Grillo G, Haas OA, Biondi A, Morra E, Larizza L. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, identification of an internal tandem duplication. Haematologica 89: 920-925, 2004.
19. Bell CA, Tynan JA, Hart KC, Meyer AN, Robertson SC, Donoghue DJ. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol Biol Cell 11: 3589-3599, 2000.
20. Benson DM Jr, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood 113: 2706-2714, 2009.
21. Berlin AA, Hogaboam CM, Lukacs NW. Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma. Lab Invest 86: 557-565, 2006.
22. Berlin AA, Lincoln P, Tomkinson A, Lukacs NW. Inhibition of stem cell factor reduces pulmonary cytokine levels during allergic airway responses. Clin Exp Immunol 136: 15-20, 2004.
23. Berlin AA, Lukacs NW. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 171: 35-39, 2005.
24. Bernex F, De Sepulveda P, Kress C, Elbaz C, Delouis C, Panthier JJ. Spatial and temporal patterns of c-kit-expressing cells in WlacZ/ and WlacZ/WlacZ mouse embryos. Development 122: 3023-3033, 1996.
25. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW Jr, Brodeur D, Zuckerman EE, Hardy WD. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320: 415-421, 1986.
26. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 10: 4121-4128, 1991.
27. Blume-Jensen P, Janknecht R, Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 8: 779-782, 1998.
28. Blume-Jensen P, Jiang G, Hyman R, Lee KF, O'Gorman S, Hunter T. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility. Nat Genet 24: 157-162, 2000.
29. Blume-Jensen P, Rönnstrand L, Gout I, Waterfield MD, Heldin C. Modulation of kit/stem cell factor receptor-induced signaling by protein kinase C. J Biol Chem 269: 21793-21802, 1994.
30. Blume-Jensen P, Siegbahn A, Stabel S, Heldin C, Rönnstrand L. Increased kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. EMBO J 12: 4199-4209, 1993.
31. Blume-Jensen P, Wernstedt C, Heldin CH, Rönnstrand L. Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells. J Biol Chem 270: 14192-14200, 1995.
32. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 130: 804-815, 2010.
33. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 72: 743-781, 2003.
34. Bondzi C, Litz J, Dent P, Krystal GW. Src family kinase activity is required for Kitmediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth Differ 11: 305-314, 2000.
35. Bougherara H, Subra F, Crépin R, Tauc P, Auclair C, Poul MA. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 7: 1525-1533, 2009.
36. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 274: 9133-9136, 1999.
37. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917-931, 2007.
38. Broudy V. Stem cell factor and hematopoiesis. Blood 90: 1345-1364, 1997.
39. Broudy VC, Lin NL, Bühring HJ, Komatsu N, Kavanagh TJ. Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer. Blood 91: 898-906, 1998.
40. Broudy VC, Lin NL, Liles WC, Corey SJ, O'Laughlin B, Mou S, Linnekin D. Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 94: 1979-1986, 1999.
41. Brown MD, Sacks DB. Protein scaffolds in MAP kinase signalling. Cell Signal 21: 462-469, 2009.
42. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
43. Burke P, Schooler K, Wiley HS. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12: 1897-1910, 2001.
44. Bäumer AT, Ten Freyhaus H, Sauer H, Wartenberg M, Kappert K, Schnabel P, Konkol C, Hescheler J, Vantler M, Rosenkranz S. Phosphatidylinositol 3-kinase-dependent membrane recruitment of Rac-1 and p47phox is critical for alpha-platelet-derived growth factor receptor-induced production of reactive oxygen species. J Biol Chem 283: 7864-7876, 2008.
45. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107: 3463-3468, 2006.
46. Caruana G, Cambareri AC, Ashman LK. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 18: 5573-5581, 1999.
47. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335: 88-89, 1988.
48. Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 23: 3067-3078, 2003.
49. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64: 5913-5919, 2004.
50. Chen M, Burgin S, Staser K, He Y, Li X, Robinson M, Jiang L, Chan RJ, Ingram D, Clapp DW. Kinase suppressor of Ras (KSR1) modulates multiple kit-ligand-dependent mast cell functions. Exp Hematol 39: 969-976, 2011.
51. Chesneau V, Becherer JD, Zheng Y, Erdjument-Bromage H, Tempst P, Blobel CP. Catalytic properties of ADAM19. J Biol Chem 278: 22331-22340, 2003.
52. Chian R, Young S, Danilkovitch-Miagkova A, Rönnstrand L, Leonard E, Ferrao P, Ashman L, Linnekin D. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 98: 1365-1373, 2001.
53. Chong H, Guan KL. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 278: 36269-36276, 2003.
54. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Böhmer FD, Gerke V, Schmidt-Arras DE, Berdel WE, Müller-Tidow C, Mann M, Serve H. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36: 326-339, 2009.
55. Coffey J, Linger R, Pugh J, Dudakia D, Sokal M, Easton DF, Timothy Bishop D, Stratton M, Huddart R, Rapley EA. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 47: 34-42, 2008.
56. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63: 175-183, 1990.
57. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825, 2004.
58. Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark SC, Crosier KE. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 82: 1151-1158, 1993.
59. d'Auriol L, Mattei MG, Andre C, Galibert F. Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum Genet 78: 374-376, 1988.
60. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
61. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
62. Dentelli P, Rosso A, Balsamo A, Colmenares Benedetto S, Zeoli A, Pegoraro M, Camussi G, Pegoraro L, Brizzi MF. C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. Blood 109: 4264-4271, 2007.
63. Dhandapani KM, Wade FM, Wakade C, Mahesh VB, Brann DW. Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFkappaB. J Neurochem 95: 9-19, 2005.
64. Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS, Van Aelst L, Pandolfi PP. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med 194: 275-284, 2001.
65. DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, Worrall JW, Diehl W, English JM, Wu JC. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance. J Biochem 147: 601-609, 2010.
66. Dorsey JF, Cunnick JM, Mane SM, Wu J. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl() K562 leukemic cells by Gab2. Blood 99: 1388-1397, 2002.
67. Drube S, Heink S, Walter S, Löhn T, Grusser M, Gerbaulet A, Berod L, Schons J, Dudeck A, Freitag J, Grotha S, Reich D, Rudeschko O, Norgauer J, Hartmann K, Roers A, Kamradt T. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 115: 3899-3906, 2010.
68. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
69. Duarte RF, Frank DA. SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. Blood 96: 3422-3430, 2000.
70. Edling CE, Pedersen M, Carlsson L, Rönnstrand L, Palmer RH, Hallberg B. Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation. Br J Haematol 136: 260-268, 2007.
71. Engström M, Karlsson R, Jönsson JI. Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand. Exp Hematol 31: 316-323, 2003.
72. Fazel SS, Chen L, Angoulvant D, Li SH, Weisel RD, Keating A, Li RK. Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB J 22: 930-940, 2008.
73. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM, Peschle C. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 102: 18081-18086, 2005.
74. Feng LX, Ravindranath N, Dym M. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem 275: 25572-25576, 2000.
75. Finotto S, Buerke M, Lingnau K, Schmitt E, Galle PR, Neurath MF. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol 107: 279-286, 2001.
76. Fiorentini D, Prata C, Maraldi T, Zambonin L, Bonsi L, Hakim G, Landi L. Contribution of reactive oxygen species to the regulation of Glut1 in two hemopoietic cell lines differing in cytokine sensitivity. Free Radic Biol Med 37: 1402-1411, 2004.
77. Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 33: 391-406, 2007.
78. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1: 1115-1124, 2002.
79. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13-24, 2005.
80. Gao XN, Lin J, Gao L, Li YH, Wang LL, Yu L. MicroRNA-193b regulates c-Kit protooncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res 35: 1226-1232, 2011.
81. Garrington TP, Ishizuka T, Papst PJ, Chayama K, Webb S, Yujiri T, Sun W, Sather S, Russell DM, Gibson SB, Keller G, Gelfand EW, Johnson GL. MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. EMBO J 19: 5387-5395, 2000.
82. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55: 185-192, 1988.
83. Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci USA 88: 8696-8699, 1991.
84. Glenney JR Jr, Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virustransformed cells are present in the membrane skeleton. J Cell Biol 108: 2401-2408, 1989.
85. Gommerman JL, Sittaro D, Klebasz NZ, Williams DA, Berger SA. Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. Blood 96: 3734-3742, 2000.
86. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880, 2001.
87. Gotoh N, Tojo A, Hino M, Yazaki Y, Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem Biophys Res Commun 186: 768-774, 1992.
88. Grovdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300: 388-395, 2004.
89. Guerrini F, Galimberti S, Ciabatti E, Brizzi S, Testi R, Pollastrini A, Falini B, Petrini M. Molecular detection of GNNK and GNNK c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia. Leukemia 21: 2056-2058, 2007.
90. Hachiya A, Kobayashi A, Ohuchi A, Takema Y, Imokawa G. The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet-Binduced pigmentation. J Invest Dermatol 116: 578-586, 2001.
91. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5: 461-466, 2003.
92. Han DC, Shen TL, Guan JL. The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions. Oncogene 20: 6315-6321, 2001.
93. Han ZB, Ren H, Zhao H, Chi Y, Chen K, Zhou B, Liu YJ, Zhang L, Xu B, Liu B, Yang R, Han ZC. Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 29: 1853-1861, 2008.
94. Hanafusa H, Torii S, Yasunaga T, Matsumoto K, Nishida E. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J Biol Chem 279: 22992-22995, 2004.
95. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 49: 615-619, 2008.
96. Hartley D, Meisner H, Corvera S. Specific association of the beta isoform of the p85 subunit of phosphatidylinositol-3 kinase with the proto-oncogene c-cbl. J Biol Chem 270: 18260-18263, 1995.
97. Hashimoto K, Matsumura I, Tsujimura T, Kim D, Ogihara H, Ikeda H, Ueda S, Mizuki M, Sugahara H, Shibayama H, Kitamura Y, Kanakura Y. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-Kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101: 1094-1102, 2003.
98. Hayashi S, Kunisada T, Ogawa M, Yamaguchi K, Nishikawa S. Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. Nucleic Acids Res 19: 1267-1271, 1991.
99. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703, 2002.
100. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349, 2003.
101. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932, 2000.
102. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett N, Crystal R, Besmer P, Lyden D, Moore M, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand. Cell 109: 625-637, 2002.
103. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 90: 570-576, 2003.
104. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391: 298-301, 1998.
105. Herraiz C, Journe F, Abdel-Malek Z, Ghanem G, Jimenez-Cervantes C, Garcia-Borron JC. Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Mol Endocrinol 25: 138-156.
106. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H, Takahashi T. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6: 2291-2296, 1991.
107. Hida T, Ueda R, Sekido Y, Hibi K, Matsuda R, Ariyoshi Y, Sugiura T, Takahashi T, Takahashi T. Ectopic expression of c-kit in small-cell lung cancer. Int J Cancer Suppl 8: 108-109, 1994.
108. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.
109. Hoeller D, Volarevic S, Dikic I. Compartmentalization of growth factor receptor signalling. Curr Opin Cell Biol 17: 107-111, 2005.
110. Hong L, Munugalavadla V, Kapur R. c-Kit-mediated overlapping and unique functional and biochemical outcomes via diverse signaling pathways. Mol Cell Biol 24: 1401-1410, 2004.
111. Hong L, Ramdas B, Chen J, Harris C, Wojchowski DM, Kapur R. KIT associated intracellular tyrosines play an essential role in EpoR co-signaling. Cell Signal 20: 1513-1520, 2008.
112. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 17: 4358-4369, 1998.
113. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13: 2339-2347, 1996.
114. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572-5581, 1997.
115. Huizinga JD, Thuneberg L, Klüppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373: 347-349, 1995.
116. Humbert M, de Blay F, Garcia G, Prud'Homme A, Leroyer C, Magnan A, Tunon-deLara JM, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O, Chanez P. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 64: 1194-1201, 2009.
117. Igoucheva O, Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 379: 790-794, 2009.
118. Ikeda H, Kanakura Y, Furitsu T, Kitayama H, Sugahara H, Nishiura T, Karasuno T, Tomiyama Y, Yamatodani A, Kanayama Y. Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor. Exp Hematol 21: 1686-1694, 1993.
119. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78: 2962-2968, 1991.
120. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21: 187-190, 1999.
121. Jahn T, Seipel P, Coutinho S, Urschel S, Schwarz K, Miething C, Serve H, Peschel C, Duyster J. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain. Oncogene 21: 4508-4520, 2002.
122. Jahn T, Seipel P, Urschel S, Peschel C, Duyster J. Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biol 22: 979-991, 2002.
123. Jahn T, Sindhu S, Gooch S, Seipel P, Lavori P, Leifheit E, Weinberg K. Direct interaction between Kit and the interleukin-7 receptor. Blood 110: 1840-1847, 2007.
124. Jain D, Moussa K, Tandon M, Culpepper-Morgan J, Proctor DD. Role of interstitial cells of Cajal in motility disorders of the bowel. Am J Gastroenterol 98: 618-624, 2003.
125. Jeon S, Kim NH, Kim JY, Lee AY. Stem cell factor induces ERM proteins phosphorylation through PI3K activation to mediate melanocyte proliferation and migration. Pigment Cell Melanoma Res 22: 77-85, 2009.
126. Jin K, Mao XO, Sun Y, Xie L, Greenberg DA. Stem cell factor stimulates neurogenesis in vitro and in vivo. J Clin Invest 110: 311-319, 2002.
127. Kamijo T, Koike K, Takeuchi K, Higuchi T, Sawai N, Kikuchi T, Tsumura H, Akiyama H, Koike T, Ishii E, Komiyama A. Analysis of synergism between stem cell factor and granulocyte-macrophage colony-stimulating factor on human megakaryoblastic cells: an increase in tyrosine phosphorylation of 145 kDa subunit of c-kit in two-factor combination. Leuk Res 21: 1097-1106, 1997.
128. Kanakura Y, Ikeda H, Kitayama H, Sugahara H, Furitsu T. Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. Leuk Lymphoma 10: 35-41, 1993.
129. Kapeller R, Prasad KV, Janssen O, Hou W, Schaffhausen BS, Rudd CE, Cantley LC. Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase. J Biol Chem 269: 1927-1933, 1994.
130. Kapur R, Zhang L. A novel mechanism of cooperation between c-Kit and erythropoietin receptor. Stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin. J Biol Chem 276: 1099-1106, 2001.
131. Katafuchi T, Li AJ, Hirota S, Kitamura Y, Hori T. Impairment of spatial learning and hippocampal synaptic potentiation in c-kit mutant rats. Learn Mem 7: 383-392, 2000.
132. Keshet E, Lyman SD, Williams DE, Anderson DM, Jenkins NA, Copeland NG, Parada LF. Embryonic RNA expression patterns of the c-kit receptor and its cognate ligand suggest multiple functional roles in mouse development. EMBO J 10: 2425-2435, 1991.
133. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. Activation and function of the mTORC1 pathway in mast cells. J Immunol 180: 4586-4595, 2008.
134. Kimura Y, Jones N, Klüppel M, Hirashima M, Tachibana K, Cohn J, Wrana J, Pawson T, Bernstein A. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc Natl Acad Sci USA 101: 6015-6020, 2004.
135. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(), c-kit(), expresses aminopeptidase N (CD13). Blood 94: 2333-2342, 1999.
136. Kissel H, Timokhina I, Hardy MP, Rothschild G, Tajima Y, Soares V, Angeles M, Whitlow SR, Manova K, Besmer P. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J 19: 1312-1326, 2000.
137. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790-798, 1995.
138. Klippel A, Escobedo JA, Hirano M, Williams LT. The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity. Mol Cell Biol 14: 2675-2685, 1994.
139. Kobi D, Steunou AL, Dembele D, Legras S, Larue L, Nieto L, Davidson I. Genomewide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene. Pigment Cell Melanoma Res 23: 404-418, 2010.
140. Koelz M, Lense J, Wrba F, Scheffler M, Dienes HP, Odenthal M. Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. Int J Oncol 38: 503-511, 2011.
141. Koike T, Hirai K, Morita Y, Nozawa Y. Stem cell factor-induced signal transduction in rat mast cells. Activation of phospholipase D but not phosphoinositide-specific phospholipase C in c-kit receptor stimulation. J Immunol 151: 359-366, 1993.
142. Koike T, Mizutani T, Hirai K, Morita Y, Nozawa Y. SCF/c-kit receptor-mediated arachidonic acid liberation in rat mast cells. Involvement of PLD activation associated tyrosine phosphorylation. Biochem Biophys Res Commun 197: 1570-1577, 1993.
143. Kozawa O, Blume-Jensen P, Heldin CH, Rönnstrand L. Involvement of phosphatidylinositol 3′-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release. Eur J Biochem 248: 149-155, 1997.
144. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 18: 2089-2099, 1998.
145. Krishnamoorthy N, Oriss TB, Paglia M, Fei M, Yarlagadda M, Vanhaesebroeck B, Ray A, Ray P. Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 14: 565-573, 2008.
146. Krystal GW, De Berry CS, Linnekin D, Litz J. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res 58: 4660-4666, 1998.
147. Kuang D, Zhao X, Xiao G, Ni J, Feng Y, Wu R, Wang G. Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK. Basic Res Cardiol 103: 265-273, 2008.
148. Kubo-Akashi C, Iseki M, Kwon SM, Takizawa H, Takatsu K, Takaki S. Roles of a conserved family of adaptor proteins, Lnk, SH2-B, APS, for mast cell development, growth, functions: APS-deficiency causes augmented degranulation and reduced actin assembly. Biochem Biophys Res Commun 315: 356-362, 2004.
149. König A, Corbacioglu S, Ballmaier M, Welte K. Downregulation of c-kit expression in human endothelial cells by inflammatory stimuli. Blood 90: 148-155, 1997.
150. Laine E, Chauvot de Beauchene I, Perahia D, Auclair C, Tchertanov L. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol 7: e1002068, 2011.
151. Lam LP, Chow RY, Berger SA. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. Biochem J 338: 131-138, 1999.
152. Langley KE, Wypych J, Mendiaz EA, Clogston CL, Parker VP, Farrar DH, Brothers MO, Satygal VN, Leslie I, Birkett NC. Purification and characterization of soluble forms of human and rat stem cell factor recombinantly expressed by Escherichia coli and by Chinese hamster ovary cells. Arch Biochem Biophys 295: 21-28, 1992.
153. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 122: 3589-3594, 2009.
154. Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 7: 51-56, 1992.
155. Lee SJ, Yoon JH, Song KS. Chrysin inhibited stem cell factor (SCF)/c-Kit complexinduced cell proliferation in human myeloid leukemia cells. Biochem Pharmacol 74: 215-225, 2007.
156. Lee Y, Mantel C, Anzai N, Braun SE, Broxmeyer HE. Transcriptional and ERK1/2- dependent synergistic upregulation of p21(cip1/waf1) associated with steel factor synergy in MO7e. Biochem Biophys Res Commun 280: 675-683, 2001.
157. Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT, McDevitt MA, Kapur R, Carter M, Metcalfe DD, Takemoto CM. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood 117: 3629-3640, 2011.
158. Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J. Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 272: 6311-6317, 1997.
159. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134, 2010.
160. Lennartsson J, Blume-Jensen P, Hermanson M, Pontén E, Carlberg M, Rönnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/ c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18: 5546-5553, 1999.
161. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23: 16-43, 2005.
162. Lennartsson J, Shivakrupa R, Linnekin D. Synergistic growth of stem cell factor and granulocyte macrophage colony-stimulating factor involves kinase-dependent and -independent contributions from c-Kit. J Biol Chem 279: 44544-44553, 2004.
163. Lennartsson J, Wernstedt C, Engström U, Hellman U, Rönnstrand L. Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk. Exp Cell Res 288: 110-118, 2003.
164. Lev S, Blechman JM, Givol D, Yarden Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncog 5: 141-168, 1994.
165. Lev S, Givol D, Yarden Y. Interkinase domain of kit contains the binding site for phosphatidylinositol 3′ kinase. Proc Natl Acad Sci USA 89: 678-682, 1992.
166. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816, 2003.
167. Li M, Naqvi N, Yahiro E, Liu K, Powell PC, Bradley WE, Martin DI, Graham RM, Dell′Italia LJ, Husain A. c-kit is required for cardiomyocyte terminal differentiation. Circ Res 102: 677-685, 2008.
168. Liang X, Wisniewski D, Strife A, Shivakrupa Clarkson B, Resh MD. Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling. J Biol Chem 277: 13732-13738, 2002.
169. Lindsey JY, Ganguly K, Brass DM, Li Z, Potts EN, Degan S, Chen H, Brockway B, Abraham SN, Berndt A, Stripp BR, Foster WM, Leikauf GD, Schulz H, Hollingsworth JW. c-Kit is essential for alveolar maintenance and protection from emphysema-like disease in mice. Am J Respir Crit Care Med 183: 1644-1652, 2011.
170. Linnekin D, DeBerry CS, Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 272: 27450-27455, 1997.
171. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 5: 1415-1422, 2006.
172. Liu L, Cutler RL, Mui AL, Krystal G. Steel factor stimulates the serine/threonine phosphorylation of the interleukin-3 receptor. J Biol Chem 269: 16774-16779, 1994.
173. Longley BJ, Tyrrell L, Ma Y, Williams DA, Halaban R, Langley K, Lu HS, Schechter NM. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci USA 94: 9017-9021, 1997.
174. Loveland KL, Schlatt S. Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. J Endocrinol 153: 337-344, 1997.
175. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, Auberger P. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22: 6785-6793, 2003.
176. Lyford GL, He CL, Soffer E, Hull TL, Strong SA, Senagore AJ, Burgart LJ, Young-Fadok T, Szurszewski JH, Farrugia G. Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 51: 496-501, 2002.
177. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-1744, 2002.
178. Mackenzie MA, Jordan SA, Budd PS, Jackson IJ. Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo. Dev Biol 192: 99-107, 1997.
179. Maddens S, Charruyer A, Plo I, Dubreuil P, Berger S, Salles B, Laurent G, Jaffrezou JP. Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect. Blood 100: 1294-1301, 2002.
180. Maeda H, Yamagata A, Nishikawa S, Yoshinaga K, Kobayashi S, Nishi K, Nishikawa S. Requirement of c-kit for development of intestinal pacemaker system. Development 116: 369-375, 1992.
181. Margulies D, Opatowsky Y, Fletcher S, Saraogi I, Tsou LK, Saha S, Lax I, Schlessinger J, Hamilton AD. Surface binding inhibitors of the SCF-KIT protein-protein interaction. Chem Biochem 10: 1955-1958, 2009.
182. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995.
183. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA. Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63: 203-211, 1990.
184. Masson K, Heiss E, Band H, Rönnstrand L. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. Biochem J 399: 59-67, 2006.
185. Matsui J, Wakabayashi T, Asada M, Yoshimatsu K, Okada M. Stem cell factor/c-kit signaling promotes the survival, migration, capillary tube formation of human umbilical vein endothelial cells. J Biol Chem 279: 18600-18607, 2004.
186. Matsui Y, Zsebo KM, Hogan BL. Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature 347: 667-669, 1990.
187. Matthews DJ, Gerritsen ME. Targeting Protein Kinases for Cancer Therapy. Chicester, UK: Wiley-Blackwell, 2009.
188. McDaniel AS, Allen JD, Park SJ, Jaffer ZM, Michels EG, Burgin SJ, Chen S, Bessler WK, Hofmann C, Ingram DA, Chernoff J, Clapp DW. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1/mast cells. Blood 112: 4646-4654, 2008.
189. Mekori YA, Gilfillan AM, Akin C, Hartmann K, Metcalfe DD. Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J Clin Immunol 21: 171-174, 2001.
190. Metcalfe DD. Mast cells and mastocytosis. Blood 112: 946-956, 2008.
191. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 77: 1033-1079, 1997.
192. Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mantel C, Broxmeyer HE. Liganddependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells. Blood 83: 137-145, 1994.
193. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-31663, 2004.
194. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC, Nowakowski J, Kassel DB, Cronin CN, McRee DE. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 278: 31461-31464, 2003.
195. Molderings GJ, Kolck UW, Scheurlen C, Brüss M, Homann J, Von Kügelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 42: 1045-1053, 2007.
196. Motro B, Wojtowicz JM, Bernstein A, van der Kooy D. Steel mutant mice are deficient in hippocampal learning but not long-term potentiation. Proc Natl Acad Sci USA 93: 1808-1813, 1996.
197. 1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells. Biochem J 342: 163-170, 1999.
198. Muciaccia B, Sette C, Paronetto MP, Barchi M, Pensini S, D'Agostino A, Gandini L, Geremia R, Stefanini M, Rossi P. Expression of a truncated form of KIT tyrosine kinase in human spermatozoa correlates with sperm DNA integrity. Hum Reprod 25: 2188-2202, 2010.
199. Munugalavadla V, Sims EC, Chan RJ, Lenz SD, Kapur R. Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT. Exp Hematol 36: 301-308, 2008.
200. Möller C, Alfredsson J, Engström M, Wootz H, Xiang Z, Lennartsson J, Jönsson JI, Nilsson G. Stem cell factor promotes mast cell survival via inactivation of FOXO3amediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 106: 1330-1336, 2005.
201. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit protooncogene receptor. Int J Cancer 52: 197-201, 1992.
202. Nishida K, Wang L, Morii E, Park SJ, Narimatsu M, Itoh S, Yamasaki S, Fujishima M, Ishihara K, Hibi M, Kitamura Y, Hirano T. Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. Blood 99: 1866-1869, 2002.
203. Nishio M, Oda A, Koizumi K, Satoh I, Sato Y, Endoh T, Tsutsumi A, Fujihara M, Ikebuchi K, Ikeda H, Koike T, Sawada KI. Stem cell factor prevents Fas-mediated apoptosis of human erythroid precursor cells with Src-family kinase dependency. Exp Hematol 29: 19-29, 2001.
204. O'Laughlin-Bunner B, Radosevic N, Taylor ML, Shivakrupa de Berry C, Metcalfe DD, Zhou M, Lowell C, Linnekin D. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood 98: 343-350, 2001.
205. Oates J, King G, Dixon AM. Strong oligomerization behavior of PDGFbeta receptor transmembrane domain and its regulation by the juxtamembrane regions. Biochim Biophys Acta 1798: 605-615.
206. Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S, Kunisada T, Sudo T, Kina T, Nakauchi H, Nishikawa S. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 174: 63-71, 1991.
207. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Nishikawa S, Miura Y, Suda T. Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. Blood 78: 1706-1712, 1991.
208. Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 5: 210-222, 2005.
209. Opdecamp K, Nakayama A, Nguyen MT, Hodgkinson CA, Pavan WJ, Arnheiter H. Melanocyte development in vivo and in neural crest cell cultures: crucial dependence on the Mitf basic-helix-loop-helix-zipper transcription factor. Development 124: 2377-2386, 1997.
210. Orr-Urtreger A, Avivi A, Zimmer Y, Givol D, Yarden Y, Lonai P. Developmental expression of c-kit, a proto-oncogene encoded by the W locus. Development 109: 911-923, 1990.
211. Ortutay C, Nore BF, Vihinen M, Smith CI. Phylogeny of Tec family kinases identification of a premetazoan origin of Btk, Bmx, Itk, Tec, Txk, and the Btk regulator SH3BP5. Adv Genet 64: 51-80, 2008.
212. Park GH, Plummer HK 3rd, Krystal GW. Selective Sp1 binding is critical for maximal activity of the human c-kit promoter. Blood 92: 4138-4149, 1998.
213. Paronetto MP, Farini D, Sammarco I, Maturo G, Vespasiani G, Geremia R, Rossi P, Sette C. Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am J Pathol 164: 1243-1251, 2004.
214. Paronetto MP, Venables JP, Elliott DJ, Geremia R, Rossi P, Sette C. Tr-kit promotes the formation of a multimolecular complex composed by Fyn, PLCgamma1 and Sam68. Oncogene 22: 8707-8715, 2003.
215. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24: 3904-3911, 2006.
216. Paulson RF, Vesely S, Siminovitch KA, Bernstein A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nat Genet 13: 309-315, 1996.
217. Pearson MA, O'Farrell AM, Dexter TM, Whetton AD, Owen-Lynch PJ, Heyworth CM. Investigation of the molecular mechanisms underlying growth factor synergy: the role of ERK 2 activation in synergy. Growth Factors 15: 293-306, 1998.
218. Pedersen M, Löfstedt T, Sun J, Holmquist-Mengelbier L, Påhlman S, Rönnstrand L. Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. Biochem Biophys Res Commun 377: 98-103, 2008.
219. Pedersen M, Rönnstrand L, Sun J. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Cell Signal 21: 413-418, 2009.
220. Phung B, Sun J, Schepsky A, Steingrimsson E, Rönnstrand L. C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One 6: e24064, 2011.
221. Piao X, Curtis JE, Minkin S, Minden MD, Bernstein A. Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood 83: 476-481, 1994.
222. Piao X, Paulson R, Van Der Geer P, Pawson T, Bernstein A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 93: 14665-14669, 1996.
223. Pietsch T. Paracrine and autocrine growth mechanisms of human stem cell factor (c-kit ligand) in myeloid leukemia. Nouv Rev Fr Hematol 35: 285-286, 1993.
224. Plo I, Lautier D, Casteran N, Dubreuil P, Arock M, Laurent G. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma. Oncogene 20: 6752-6763, 2001.
225. Price DJ, Rivnay B, Fu Y, Jiang S, Avraham S, Avraham H. Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes. J Biol Chem 272: 5915-5920, 1997.
226. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase familyoncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 7: 1003-1011, 1988.
227. Ratajczak MZ, Perrotti D, Melotti P, Powzaniuk M, Calabretta B, Onodera K, Kregenow DA, Machalinski B, Gewirtz AM. Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. Blood 91: 1934-1946, 1998.
228. Ray P, Krishnamoorthy N, Oriss TB, Ray A. Signaling of c-kit in dendritic cells influences adaptive immunity. Ann NY Acad Sci 1183: 104-122, 2010.
229. Reinhard C, Meyer B, Fuchs H, Stoeger T, Eder G, Rüschendorf F, Heyder J, Nürnberg P, de Angelis MH, Schulz H. Genomewide linkage analysis identifies novel genetic Loci for lung function in mice. Am J Respir Crit Care Med 171: 880-888, 2005.
230. Reith AD, Ellis C, Lyman SD, Anderson DM, Williams DE, Bernstein A, Pawson T. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J 10: 2451-2459, 1991.
231. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Muller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23: 477-485, 2009.
232. Ropers HH, Craig IW. Report of the committee on the genetic constitution of chromosomes 12 and 13. Cytogenet Cell Genet 51: 259-279, 1989.
233. Rossi P, Dolci S, Sette C, Geremia R. Molecular mechanisms utilized by alternative c-kit gene products in the control of spermatogonial proliferation and sperm-mediated egg activation. Andrologia 35: 71-78, 2003.
234. Rossi P, Marziali G, Albanesi C, Charlesworth A, Geremia R, Sorrentino V. A novel c-kit transcript, potentially encoding a truncated receptor, originates within a kit gene intron in mouse spermatids. Dev Biol 152: 203-207, 1992.
235. Russell ES. Hereditary anemias of the mouse: a review for geneticists. Adv Genet 20: 357-459, 1979.
236. Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 94: 486-491, 2003.
237. Samayawardhena LA, Hu J, Stein PL, Craig AW. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Cell Signal 18: 1447-1454, 2006.
238. Samayawardhena LA, Pallen CJ. Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 283: 29175-29185, 2008.
239. Sangle NA, Perkins SL. Core-binding factor acute myeloid leukemia. Arch Pathol Lab Med 135: 1504-1509, 2011.
240. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005.
241. Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, Griffin JD. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem 272: 10248-10253, 1997.
242. Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 93: 2928-2935, 1999.
243. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66: 473-481, 2006.
244. Schmidt U, van den Akker E, Parren-van Amelsvoort M, Litos G, de Bruijn M, Gutierrez L, Hendriks RW, Ellmeier W, Löwenberg B, Beug H, von Lindern M. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med 199: 785-795, 2004.
245. Scott G, Ewing J, Ryan D, Abboud C. Stem cell factor regulates human melanocytematrix interactions. Pigment Cell Res 7: 44-51, 1994.
246. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y, Takahashi T. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51: 2416-2419, 1991.
247. Serve H, Hsu Y, Besmer P. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in cos-1 cells. J Biol Chem 269: 6026-6030, 1994.
248. Sette C, Bevilacqua A, Bianchini A, Mangia F, Geremia R, Rossi P. Parthenogenetic activation of mouse eggs by microinjection of a truncated c-kit tyrosine kinase present in spermatozoa. Development 124: 2267-2274, 1997.
249. Sette C, Bevilacqua A, Geremia R, Rossi P. Involvement of phospholipase Cgamma1 in mouse egg activation induced by a truncated form of the C-kit tyrosine kinase present in spermatozoa. J Cell Biol 142: 1063-1074, 1998.
250. Sette C, Paronetto MP, Barchi M, Bevilacqua A, Geremia R, Rossi P. Tr-kit-induced resumption of the cell cycle in mouse eggs requires activation of a Src-like kinase. EMBO J 21: 5386-5395, 2002.
251. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401, 2004.
252. Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. KIT mutations, not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 107: 1806-1809, 2006.
253. Shimizu Y, Ashman LK, Du Z, Schwartz LB. Internalization of Kit together with stem cell factor on human fetal liver-derived mast cells: new protein and RNA synthesis are required for reappearance of Kit. J Immunol 156: 3443-3449, 1996.
254. Shivakrupa R, Linnekin D. Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells. Cell Signal 17: 103-109, 2005.
255. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2: 249-256, 2000.
256. Simon C, Dondi E, Chaix A, de Sepulveda P, Kubiseski TJ, Varin-Blank N, Velazquez L. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112: 4039-4047, 2008.
257. Smith JA, Samayawardhena LA, Craig AW. Fps/Fes protein-tyrosine kinase regulates mast cell adhesion and migration downstream of Kit and beta1 integrin receptors. Cell Signal 22: 427-436, 2010.
258. Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA 74: 3065-3067, 1977.
259. Sui X, Krantz SB, You M, Zhao Z. Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 92: 1142-1149, 1998.
260. Sun J, Pedersen M, Bengtsson S, Rönnstrand L. Grb2 mediates negative regulation of stem cell factor receptor/c-Kit signaling by recruitment of Cbl. Exp Cell Res 313: 3935-3942, 2007.
261. Sun J, Pedersen M, Rönnstrand L. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. J Biol Chem 284: 11039-11047, 2009.
262. Sun J, Pedersen M, Rönnstrand L. Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit. J Biol Chem 283: 27444-27451, 2008.
263. Sun L, Lee J, Fine HA. Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest 113: 1364-1374, 2004.
264. Sundström M, Alfredsson J, Olsson N, Nilsson G. Stem cell factor-induced migration of mast cells requires p38 mitogen-activated protein kinase activity. Exp Cell Res 267: 144-151, 2001.
265. Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, Theou-Anton N, Lemoine A, Blay JY, Emile JF. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res 14: 2285-2294, 2008.
266. Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 195: 151-160, 2002.
267. Takaki S, Sauer K, Iritani BM, Chien S, Ebihara Y, Tsuji K, Takatsu K, Perlmutter RM. Control of B cell production by the adaptor protein lnk. Definition Of a conserved family of signal-modulating proteins. Immunity 13: 599-609, 2000.
268. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294-299, 2004.
269. Tanaka S, Ouchi T, Hanafusa H. Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G. Proc Natl Acad Sci USA 94: 2356-2361, 1997.
270. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 278: 4847-4853, 2003.
271. Taylor ML, Dastych J, Sehgal D, Sundström M, Nilsson G, Akin C, Mage RG, Metcalfe DD. The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis. Blood 98: 1195-1199, 2001.
272. Taylor WE, Najmabadi H, Strathearn M, Jou NT, Liebling M, Rajavashisth T, Chanani N, Phung L, Bhasin S. Human stem cell factor promoter deoxyribonucleic acid sequence and regulation by cyclic 3′,5′-adenosine monophosphate in a Sertoli cell line. Endocrinology 137: 5407-5414, 1996.
273. Theou-Anton N, Tabone S, Brouty-Boye D, Saffroy R, Rönnstrand L, Lemoine A, Emile JF. Coexpression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 94: 1180-1185, 2006.
274. Thomas SM, Soriano P, Imamoto A. Specific and redundant roles of Src and Fyn in organizing the cytoskeleton. Nature 376: 267-271, 1995.
275. Thömmes K, Lennartsson J, Carlberg M, Rönnstrand L. Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. Biochem J 341: 211-216, 1999.
276. Timokhina I, Kissel H, Stella G, Besmer P. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J 17: 6250-6262, 1998.
277. Treff NR, Dement GA, Adair JE, Britt RL, Nie R, Shima JE, Taylor WE, Reeves R. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells. Oncogene 23: 8557-8562, 2004.
278. Trieselmann NZ, Soboloff J, Berger SA. Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci 60: 759-766, 2003.
279. Tsujimura T, Morii E, Nozaki M, Hashimoto K, Moriyama Y, Takebayashi K, Kondo T, Kanakura Y, Kitamura Y. Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. Blood 88: 1225-1233, 1996.
280. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058, 2001.
281. Ueda S, Mizuki M, Ikeda H, Tsujimura T, Matsumura I, Nakano K, Daino H, Honda Z, Sonoyama J, Shibayama H, Sugahara H, Machii T, Kanakura Y. Critical roles of c-kit tyrosine residues 567 and 719 in stem cell factor-induced chemotaxis: contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration. Blood 99: 3342-3349, 2002.
282. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 22: 965-977, 2002.
283. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27: 693-733, 2009.
284. Van Dijk TB, van Den Akker E, Amelsvoort MP, Mano H, Löwenberg B, von Lindern M. Stem cell factor induces phosphatidylinositol 3′-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. Blood 96: 3406-3413, 2000.
285. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 110: 2593-2599, 2007.
286. Von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19: 1670-1671, 2005.
287. Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK, Rönnstrand L. Src family kinases are involved in the differential signaling from two splice forms of c-Kit. J Biol Chem 278: 9159-9166, 2003.
288. Wandzioch E, Edling CE, Palmer RH, Carlsson L, Hallberg B. Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. Blood 104: 51-57, 2004.
289. Wang CH, Verma S, Hsieh IC, Hung A, Cheng TT, Wang SY, Liu YC, Stanford WL, Weisel RD, Li RK, Cherng WJ. Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 27: 540-547, 2007.
290. Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y, Xiong SM, Mi JQ, Chen Z, Ren R, Chen SJ. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 108: 2450-2455.
291. Ward SM, Burns AJ, Torihashi S, Harney SC, Sanders KM. Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. Am J Physiol Cell Physiol 269: C1577-C1585, 1995.
292. Ward SM, Burns AJ, Torihashi S, Sanders KM. Mutation of the proto-oncogene c-kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. J Physiol 480: 91-97, 1994.
293. Waskow C, Terszowski G, Costa C, Gassmann M, Rodewald HR. Rescue of lethal c-KitW/W mice by erythropoietin. Blood 104: 1688-1695, 2004.
294. Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 16: 287-296, 2003.
295. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141, 2005.
296. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS. Identification of a ligand for the c-kit proto-oncogene. Cell 63: 167-174, 1990.
297. Wisniewski D, Strife A, Clarkson B. c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells. Leukemia 10: 1436-1442, 1996.
298. Wollberg P, Lennartsson J, Gottfridsson E, Yoshimura A, Rönnstrand L. The adapter protein APS associates to the multifunctional docking sites Tyr568 and Tyr936 in c-Kit: possible role in v-Kit transformation. Biochem J 370: 1033-1038, 2003.
299. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80: 568-574, 2010.
300. Wu H, Klingmüller U, Besmer P, Lodish HF. Interaction of the erythropoietin and stem-cell-factor receptors. Nature 377: 242-246, 1995.
301. Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, Fisher DZ, Fisher DE. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 14: 301-312, 2000.
302. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 27: 267-282, 2007.
303. Yamamoto K, Tojo A, Aoki N, Shibuya M. Characterization of the promoter region of the human c-kit proto-oncogene. Jpn J Cancer Res 84: 1136-1144, 1993.
304. 1 phase to allow cell-cycle progression. Curr Biol 16: 1171-1182, 2006.
305. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
306. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6: 3341-3351, 1987.
307. Yasuda H, Galli SJ, Geissler EN. Cloning and functional analysis of the mouse c-kit promoter. Biochem Biophys Res Commun 191: 893-901, 1993.
308. Yee NS, Hsiau CW, Serve H, Vosseller K, Besmer P. Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C. J Biol Chem 269: 31991-31998, 1994.
309. Yu M, Luo J, Yang W, Wang Y, Mizuki M, Kanakura Y, Besmer P, Neel BG, Gu H. The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 281: 28615-28626, 2006.
310. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130: 323-334, 2007.
311. Zadjali F, Pike AC, Vesterlund M, Sun J, Wu C, Li SS, Rönnstrand L, Knapp S, Bullock AN, Flores-Morales A. Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem 286: 480-490, 2011.
312. Zeng S, Xu Z, Lipkowitz S, Longley JB. Regulation of stem cell factor receptor signaling by CBL family proteins (CBL-B/c-CBL). Blood 2004.
313. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628, 1996.
314. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 13: 341-355, 2004.
315. Zhang Z, Zhang R, Joachimiak A, Schlessinger J, Kong XP. Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation. Proc Natl Acad Sci USA 97: 7732-7737, 2000.
316. Zhu WM, Dong WF, Minden M. Alternate splicing creates two forms of the human kit protein. Leuk Lymphoma 12: 441-447, 1994.
317. Zou J, Zhu F, Liu J, Wang W, Zhang R, Garlisi CG, Liu YH, Wang S, Shah H, Wan Y, Umland SP. Catalytic activity of human ADAM33. J Biol Chem 279: 9818-9830, 2004.